Yahoo Finance report covering Omada Health Inc. (OMDA) market action, institutional positioning, and fundamental catalysts.
Why OMDA Stock dropped -4.68% Today — RQD Quant Desk Flash
Omada Health Inc. (OMDA) carries a Roarable Rating of D+ (Sell) with 53/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is OMDA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Omada Health Inc. (NASDAQ: OMDA) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $18.73 (-4.68% 1D, market cap $1.15B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, OMDA ranks #232 in composite RQD confidence.
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does OMDA compare to INNV and USPH in the Health Care sector?
▼
Within the Health Care sector (Medical/Nursing Services), OMDA carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of 65.7%, and ROIC of -15.7%. By comparison, INNV (InnovAge Holding Corp.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC -10.2%, cap $1.25B) and USPH (U.S. Physical Therapy Inc.) posts a B- grade (70/100 RQD, P/E 32.6x, ROIC 11.5%, cap $1.28B). Among the 5-stock peer group, USPH leads on earnings multiple (32.6x) while USPH leads on capital efficiency (11.5% ROIC).
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for OMDA?
▼
Per OMDA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001611115), Omada Health Inc. generated $260.2M in revenue (+53.2% YoY), -$12.8M in net income, and $16.9M in free cash flow against $305.4M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 8.93 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL FY 2025 (10-K): 6.5% FCF Margin ($16.9M FCF) & 65.7% Gross Margin
Dilution Drag (+1.64% YoY Shares) & executive Form 4 sales trim 14 pts from alignment
⚔️ Adversarial Opposing Case: What Could Spark a OMDA Turnaround Squeeze
While OMDA currently carries a cautious 53/100 (D+) rating due to Insider Conviction & Share Dilution (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Clean SEC annual filing review with no major hidden accounting time-bombs.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($20.56) and Max Pain ($19.67) forces dealer call-delta covering toward $27.44.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.64% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Why OMDA Stock dropped -4.68% Today — RQD Quant Desk Flash
Omada Health Inc. (OMDA) dropped -4.68% to $18.73, trading at 53% of its 52-week range ($10.28 – $26.13). Stretched risk/reward at current multiples (-16% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 53% of its 52-week range ($10.28 – $26.13) with RSI-14 at 44.5 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±10.8% around $18.73 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 65.7% gross margin and $16.9M annual free cash flow.
Seeking Alpha report covering Omada Health Inc. (OMDA) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Omada Health Inc. (OMDA) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Omada Health Inc. (OMDA) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Omada Health Inc. (OMDA) market action, institutional positioning, and fundamental catalysts.
Investing.com UK report covering Omada Health Inc. (OMDA) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Omada Health Inc. (OMDA) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Omada Health Inc. (OMDA) market action, institutional positioning, and fundamental catalysts.
Barclays analyst Saket Kalia maintains Omada Health (NASDAQ:OMDA) with a Overweight and lowers the price target from $27 to $24.
OrthoPediatrics, Omada Health, Enovis, Myomo and FIGS span the full arc of physical therapy, from childhood care and prevention to recovery and the professionals who deliver it NEW YORK, Oct. 22, 2026 (GLOBE NEWSWIRE) --
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring OMDA)
- ✓Walkthrough of OMDA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
OMDA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +53.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on OMDA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for OMDA. Explore sector supply chains on /butterfly.
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OMDA)
1. Head-to-Head Health Care Peer Comparison (OMDA vs. INNV, USPH, PNTG, TDOC)
Industry: Medical/Nursing Services (29 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Omada Health Inc. (OMDA) ranks #232 by composite RQD confidence (53/100, grade D+) and #339 by equity capitalization ($1.15B). Within this direct 5-issuer industry benchmark cohort, USPH leads on earnings valuation at 32.6x trailing P/E, while USPH leads on capital efficiency and profitability with 11.5% ROIC and 19.2% gross margin. USPH currently holds the highest overall quantitative score in the immediate peer group at 70/100 (B-) compared with OMDA at 53/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| OMDA
ACTIVE
Omada Health Inc. | D+ | 53/100 | — | 65.7% | -15.7% | -4.68% | $1.15B | Benchmark Subject |
| INNV InnovAge Holding Corp. | D+ | 52/100 | — | 18.0% | -10.2% | -0.54% | $1.25B | /innv-vs-omda → |
| USPH U.S. Physical Therapy Inc. | B- | 70/100 | 32.6x | 19.2% | 11.5% | -0.85% | $1.28B | /usph-vs-omda → |
| PNTG The Pennant Group Inc. | C | 64/100 | 50.2x | — | 11.0% | -1.93% | $1.46B | /pntg-vs-omda → |
| TDOC Teladoc Health Inc. | D+ | 55/100 | — | — | -17.0% | -2.52% | $1.55B | /tdoc-vs-omda → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001611115In its most recent audited fiscal period (FY2025, filed 2025-12-31), Omada Health Inc. (OMDA) reported GAAP revenue of $260.2M (+53.2% vs. FY2024 revenue of $169.8M , and +111.9% cumulative change since FY2023) , GAAP net income of -$12.8M, operating cash flow of $18.3M, and free cash flow of $16.9M (+148.7% YoY). On the balance sheet, OMDA closed FY2025 with $305.4M in total assets against $0 in total debt (Altman Z-Score: 8.93, Piotroski F-Score: 7/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $260.2M | -$12.8M | $18.3M | $16.9M | $305.4M | — |
| FY2024 (FY) | 2024-12-31 | $169.8M | -$47.1M | -$34.2M | -$34.8M | $150.9M | — |
| FY2023 (FY) | 2023-12-31 | $122.8M | -$67.5M | -$49.7M | -$49.7M | — | — |
3. OMDA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs OMDA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Omada Health Inc. (NASDAQ: OMDA) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $18.73 (-4.68% 1D, market cap $1.15B). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 6/20. Across 1016 tracked Health Care issuers, OMDA ranks #232 in composite RQD confidence.
How does OMDA compare to INNV and USPH in the Health Care sector?
Within the Health Care sector (Medical/Nursing Services), OMDA carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of 65.7%, and ROIC of -15.7%. By comparison, INNV (InnovAge Holding Corp.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC -10.2%, cap $1.25B) and USPH (U.S. Physical Therapy Inc.) posts a B- grade (70/100 RQD, P/E 32.6x, ROIC 11.5%, cap $1.28B). Among the 5-stock peer group, USPH leads on earnings multiple (32.6x) while USPH leads on capital efficiency (11.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for OMDA?
Per OMDA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001611115), Omada Health Inc. generated $260.2M in revenue (+53.2% YoY), -$12.8M in net income, and $16.9M in free cash flow against $305.4M in total assets and $0 in total debt. Key quantitative strengths: Clean SEC annual filing review with no major hidden accounting time-bombs.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is OMDA trading relative to its 50-day, 200-day, and 52-week technical levels?
OMDA last traded at $18.73 (-4.68% on volume of 958,664 shares), positioning the stock -8.90% below its 50-day simple moving average ($20.56) and +5.70% above its 200-day simple moving average ($17.72). Across its 52-week range of $10.28 to $26.13, OMDA sits at the 53.3% percentile with a 14-day RSI of 44.5 (NEUTRAL RANGE) and an implied next-earnings move of ±10.8% ($16.71 to $20.75).
OMDA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is OMDA stock moving today?
Why OMDA Stock dropped -4.68% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-16% return on capital) under elevated 10-year interest-rate pressure.
OMDA — Omada Health Inc.: What the Facts Mean to a Prospective Investor
Roarable Rating Brief: What This Means to a Prospective Investor
The Roarable RQD Score is 55 out of 100, graded D+, with the verdict "Roarable Sell — Weak Fundamentals / Trim," per the Roarable RQD rating. The score is built from five pillars:
- Fundamental Cash Engine: 13 / 20. Per the Roarable RQD rating, this reflects ROIC of -15.7% and an FCF yield of 1.41%. For a prospective investor, negative ROIC means the business is not currently earning returns above its capital base, and a 1.41% FCF yield is a thin cash return relative to the $19.65 price.
- Whale 13F Flow: 9 / 20. The rating describes this pillar as institutional accumulation and options positioning. The source data does not include 13F holder detail (see Analyst View section), so the pillar score cannot be traced to specific holders here.
- Insider Conviction: 6 / 20. The rating describes SEC Form 4 and Congressional PTR cluster flow. No insider transaction records are supplied in the source data, so the weak score is not independently verifiable from this dossier.
- Macro Regime Fit: 11 / 20. Per the rating, beta is 1.0 and sector sensitivity is reflected in this pillar. Per the market data, beta is 1.0, meaning the stock is expected to move in line with the broader market.
- Forensic Balance Sheet: 16 / 20. The strongest pillar, per the rating: Altman Z 8.93, Piotroski F 7/9, and Debt/Equity 0.5. This indicates a relatively sound balance sheet even though the operating business is loss-making.
Taken together, the rating points to a business with a stronger balance sheet than its earnings profile would suggest. Upside drivers would need to come from a turn toward positive ROIC and cash generation; the rating's valuation tradeoff is that the stock's price already reflects significant expectations relative to current returns. Because the verdict is a Sell/Trim rating, the rating itself flags more downside risk than upside in its current form.
Business
Omada Health Inc. (OMDA) is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Nursing Services industry, per the company profile. The source data does not describe its products, customers, or revenue model. The market capitalization is $1.2B, per the company profile and market data.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $260.2M | $-12.0M | $-12.8M | N/A | $16.9M | $222.0M | N/A |
| FY 2024 | $169.8M | $-43.7M | $-47.1M | N/A | $-34.8M | $76.4M | N/A |
| FY 2023 | $122.8M | $-66.0M | $-67.5M | N/A | $-49.7M | N/A | N/A |
Per the SEC financials, revenue grew from $122.8M in FY 2023 to $260.2M in FY 2025, while operating losses narrowed from $-66.0M to $-12.0M. Per the market data, the gross margin is 65.7%, the operating margin is -4.6%, and the net margin is -4.9%. ROIC is -15.7%. The Altman Z-Score is 8.93 and the Piotroski F-Score is 7/9, both per the Roarable RQD rating, with Debt/Equity at 0.5. Reported cash rose to $222.0M in FY 2025, per the SEC financials.
Recent Catalysts & News Wire Analysis
Per the news wire, six items reference OMDA: a Yahoo Finance piece questioning long-term targets and valuation; a Seeking Alpha piece titled that it shows promising growth but questions the moat; a Simply Wall St piece on renewed attention; a TradingView report that Freedom Capital Markets maintains a Buy rating with a $35 price target; a kalkine.ca report that the stock slid 10.1% on an earnings tag; and an Investing.com UK report that Citizens reiterated its rating ahead of Q3 results. The news wire shows mixed sentiment, with several items flagged YELLOW and one flagged GREEN.
Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals.
Open Questions
- What is the company's product mix and revenue model behind the $260.2M FY 2025 revenue figure?
- What drove the earnings decline cited in the kalkine.ca report, and what were the actual EPS and forward estimates?
- Why is FY 2025 FCF positive at $16.9M while FY 2025 net income is $-12.8M, and what is the cash bridge?
- What are the debt balances, since the debt field is reported as N/A for all periods?
- What institutional and insider holdings underpin the whale and insider pillar scores?
OMDA Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Omada Health Inc. (OMDA) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering Omada Health Inc. (OMDA) market action, institutional positioning, and fundamental catalysts.
Seeking Alpha report covering Omada Health Inc. (OMDA) market action, institutional positioning, and fundamental catalysts.
Simply Wall St report covering Omada Health Inc. (OMDA) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Omada Health Inc. (OMDA) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Omada Health Inc. (OMDA) market action, institutional positioning, and fundamental catalysts.
Investing.com UK report covering Omada Health Inc. (OMDA) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Omada Health Inc. (OMDA) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering Omada Health Inc. (OMDA) market action, institutional positioning, and fundamental catalysts.
OMDA Bull vs. Bear Conversation Board — What's Your Call at $18.73?
🔥 Official Bull vs. Bear Debate: Is OMDA (D+ • RQD 55/100) a Buy at $19.65?
Welcome to the OMDA (Omada Health Inc.) Roar Pit. Current RQD Composite is 55/100 (Roarable Sell — Weak Fundamentals / Trim) in Medical/Nursing Services. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Pump the brakes on OMDA — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on OMDA, but look at what you are paying: current EV/EBITDA multiples with 65.7% gross margins. Unless Omada Health Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
OMDA cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on OMDA, the market is fixating on short-term headline noise in Medical/Nursing Services and ignoring the balance sheet and cash flow trajectory. At $19.65 (52-wk range $10.28 - $26.13), any beat on forward guidance forces shorts and underweight funds to chase.